콘텐츠로 건너뛰기
주식/증권 📈 긍정적

EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?

요약

Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.